


# Biocon

**BSE SENSEX**  
80,623

**S&P CNX**  
24,596

## Conference Call Details


**Date:** 8<sup>th</sup> Aug 2025

**Time:** 9:00 am IST

**Dial-in details:**

Zoom [Link](#)

### Financials & Valuations (INR b)

Y/E MARCH	FY25	FY26E	FY27E
Sales	152.6	180.6	206.4
EBITDA	31.7	38.6	44.1
Adj. PAT	2.5	5.3	11.1
EBIT Margin (%)	9.9	10.8	11.7
Cons. Adj. EPS (INR)	2.0	4.4	9.3
EPS Gr. (%)	13.3	117	110
BV/Sh. (INR)	180.4	184.5	193.3

### Ratios

Net D:E	0.8	0.8	0.8
RoE (%)	1.2	2.4	4.9
RoCE (%)	2.7	3.1	4.1
Payout (%)	23.2	5.6	5.6

### Valuations

P/E (x)	192.9	82.5	39.4
EV/EBITDA (x)	18.9	16.2	14.4
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	3.9	-0.4	-1.0
EV/Sales (x)	3.9	3.5	3.1

## CMP: INR365

### Generics led miss on earnings

- BIOS 1QFY26 revenues grew 15% YoY to INR39.4b (est. INR42.4b).
- Revenue growth was led by:
- Generics sales, up 5.7% YoY to INR7b (17% of sales).
- Research services (22% of sales), up 11% YoY to INR8.8b.
- Biosimilars (61% of sales), which rose 28.6% YoY to INR24.5b.
- Gross margin (GM), contracted 120bp YoY to 63.5%.
- EBITDA margin expanded 90bp YoY to 19% (est: 21.5%) due to lower R&D/employee cost (-140bp/-60bp YoY as a % of sales).
- The EBITDA margin for Biocon Biologics stood at 20.8% for 1QFY26 (down 200bps YoY/down 110bps QoQ).
- The EBITDA margin of Syngene is 25.6% for the quarter (up 410bp YoY/down 810bp QoQ basis).
- The Generic business registered EBITDA margin of 1.9% vs 8.9% YoY and (23.2% QoQ).
- EBITDA grew 20.5% YoY to INR7.5b (est: INR9b) for the quarter.
- Adj. PAT came in at INR300m vs loss of INR1.6b YoY.
- Revenue/EBITDA/PAT miss BBG estimates by 2%/11%/71%.

### Key highlights

- During the quarter, the generics business margin was considerably impacted due to higher opex related to newer facilities.
- BIOS launched g-Micafungin and Everolimus in US in 1QFY26. BIOS received approval for Liraglutide for India market.
- BIOS received approval for Insulin Aspart during the quarter.
- BIOS launched aflibercept in Canada market during the quarter.
- Biocon launched Yesintek (b-Ustekinumab) in key European markets. It received positive opinion for Yesafili (bAflibercept).

# Quarterly performance (Consolidated)

Y/E March	FY25				FY26E				FY25	FY26E	Var%
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		1QE	vs Est
<b>Net Sales</b>	<b>34,329</b>	<b>35,904</b>	<b>38,214</b>	<b>44,170</b>	<b>39,420</b>	<b>43,955</b>	<b>46,634</b>	<b>47,646</b>	<b>1,52,617</b>	<b>42,406</b>	<b>-7.0%</b>
YoY Change (%)	0.3	3.7	6.0	12.8	14.8	22.4	22.0	7.9	5.9	23.5	
Total Expenditure	<b>28,120</b>	<b>29,040</b>	<b>30,357</b>	<b>33,390</b>	<b>31,940</b>	<b>34,944</b>	<b>36,468</b>	<b>37,307</b>	<b>1,20,907</b>	33,288	
<b>EBITDA</b>	<b>6,209</b>	<b>6,864</b>	<b>7,857</b>	<b>10,780</b>	<b>7,480</b>	<b>9,011</b>	<b>10,166</b>	<b>10,339</b>	<b>31,710</b>	<b>9,117</b>	<b>-18.0%</b>
YoY Change (%)	-12.9	-7.4	36.2	17.7	20.5	31.3	29.4	-4.1	7.6	46.8	
Margins (%)	18.1	19.1	20.6	24.4	19.0	20.5	21.8	21.7	20.8	21.5	
Depreciation	4,050	4,200	4,250	4,360	4,550	4,593	4,873	4,979	16,860	4,358	
<b>EBIT</b>	<b>2,159</b>	<b>2,664</b>	<b>3,607</b>	<b>6,420</b>	<b>2,930</b>	<b>4,417</b>	<b>5,293</b>	<b>5,360</b>	<b>14,850</b>	<b>4,759</b>	
YoY Change (%)	-39.2	-24.4	123.1	26.1	35.7	65.8	46.7	-16.5	7.8	120.4	
Interest	2,360	2,260	2,230	2,120	2,770	2,050	1,950	1,850	8,970	2,100	
Other Income	767	330	350	370	800	415	430	445	1,817	410	
Extraordinary Income	10,893	260	-163	210	0	0	0	0	11,200	0	
Share of Profit/Loss from Associates	0	0	0	0	0	0	0	0	0	0	
<b>PBT</b>	<b>11,459</b>	<b>994</b>	<b>1,564</b>	<b>4,880</b>	<b>960</b>	<b>2,782</b>	<b>3,773</b>	<b>3,955</b>	<b>18,897</b>	<b>3,069</b>	<b>-68.7%</b>
Tax	2,840	710	750	280	80	790	1,087	1,147	4,580	859	
Rate (%)	24.8	71.4	47.9	5.7	8.3	28.4	28.8	29.0	24.2	28.0	
Minority Interest	2,030	430	560	1,150	580	1,135	1,140	1,160	4,170	1,120	
<b>PAT</b>	<b>6,589</b>	<b>-146</b>	<b>254</b>	<b>3,450</b>	<b>300</b>	<b>857</b>	<b>1,546</b>	<b>1,648</b>	<b>10,147</b>	<b>1,090</b>	<b>-72.5%</b>
<b>Adj PAT</b>	<b>-1,604</b>	<b>365</b>	<b>439</b>	<b>3,252</b>	<b>300</b>	<b>857</b>	<b>1,546</b>	<b>1,648</b>	<b>2,452</b>	<b>1,090</b>	<b>-72.5%</b>
YoY Change (%)	-260.4	-74.7	-125.8	128.4	-118.7	134.7	252.1	-49.3	13.2	-167.9	
Margins (%)	19.2	-0.4	0.7	7.8	0.8	2.0	3.3	3.5	6.6	2.6	